

## Product datasheet for TL312267V

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ICAM4 Human shRNA Lentiviral Particle (Locus ID 3386)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** ICAM4 Human shRNA Lentiviral Particle (Locus ID 3386)

Locus ID: 3386

CD242: LW Synonyms:

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ICAM4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

BC000046, NM 001039132, NM 001544, NM 022377, NM 001039132.1, NM 001039132.2, RefSeq:

NM 001544.1, NM 001544.2, NM 001544.3, NM 022377.2, NM 022377.3, BC000046.2,

BC029364, BC029364.1, NM 001544.5, NM 001039132.3

**UniProt ID:** Q14773

This gene encodes the Landsteiner-Wiener (LW) blood group antigen(s) that belongs to the **Summary:** 

> immunoglobulin (Ig) superfamily, and that shares similarity with the intercellular adhesion molecule (ICAM) protein family. This ICAM protein contains 2 lg-like C2-type domains and binds to the leukocyte adhesion LFA-1 protein. The molecular basis of the LW(A)/LW(B) blood group antigens is a single aa variation at position 100; Gln-100=LW(A) and Arg-100=LW(B). Alternative splicing results in multiple transcript variants encoding distinct isoforms.

[provided by RefSeq, Jul 2008]

These shRNA constructs were designed against multiple splice variants at this gene locus. To shRNA Design:

be certain that your variant of interest is targeted, please contact <a href="techsupport@origene.com">techsupport@origene.com</a>.

If you need a special design or shRNA sequence, please utilize our custom shRNA service.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).